Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis

Abstract

Purpose A prostate-specific antigen (PSA) cutoff of 4 ng/mL has been widely used for prostate cancer screening in population-based settings. However, the accuracy of PSA below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting is inconclusive. We systematically reviewed the accuracy of PSA below 4 ng/mL cutoff in a hospital setting. Materials and Methods We systematically reviewed the literature by searching major databases until March 2020, and a meta-analysis and quality assessment were performed. Results A total of 11 studies were included at the completion of the screening process. The meta-analysis showed a sensitivity of 0.92 and a specificity of 0.16 for a PSA cutoff below 4 ng/mL. The area under the hierarchical summary receiver operating characteristic curve was 0.87, the positive likelihood ratio was 1.23, the negative likelihood ratio was 0.46, and the diagnostic odds ratio was 2.64. PSA sensitivities and specificities varied according to the cutoff range: 0.94 and 0.17 for 2 to 2.99 ng/mL, and 0.92 and 0.16 for 3 to 3.99 ng/mL, respectively. No significant differences in the sensitivity and specificity of PSA cutoffs in the range of 2 to 2.99 ng/mL and 3 to 3.99 ng/mL were found. Conclusions Although a PSA cutoff <3 ng/mL is relatively more sensitive and specific than PSA ≥3 ng/mL, no significant differences in sensitivity and specificity were found in the diagnosis of prostate cancer. Therefore, clinicians should choose an appropriate PSA cutoff on the basis of clinical circumstances and patients’ characteristics.

New insights on the early prostate cancer diagnosis in a real-world setting

“…Another interesting study from Korean group Jin et al [ 6 ], recently demonstrated PSA with a cut-off value <3 ng/mL is relatively more sensitive and specific than PSA ≥3 ng/mL and did not show any significant differences neither sensitivity nor specificity during the diagnosis of PCa. Due to this reason, Jin et al [ 6 ], offers clinicians may select the appropriate PSA cut-off value based on clinical episode regarding patients’ attribution related to the risk of PCa.…”